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Background: Intratumoral LTX-315 disintegrates cytoplasmic organelles with release of tumor 
antigens in preclinical models accompanied by increase in tumor-infiltrating lymphocytes (TILs). LTX-
315 induced complete regression in several rodent models, with systemic immune responses. LTX-
315 is strongly synergistic preclinically with immune checkpoint inhibitors (ICI). We are conducting a 
phase 1 trial to evaluate LTX-315 in combination therapy.  
Methods: Patients with advanced metastatic solid tumours received injections of LTX-315 into a 
single accessible tumour over 6 weeks. Additional injections could be administered thereafter every 
2 weeks. Biopsies of injected lesions were taken at baseline, and on treatment.  
Results: 28 have been enrolled to date, median age is 58 (range 32-80) and median prior treatments 
2 (range 1-14). LTX-315 monotherapy was administered at doses of 2-7mg to a median of 1.8 tumour 
lesions (range 1-6) for a median of 9 weeks (range 1-33). In 24 patients all LTX-315-related adverse 
events were CTC grade 1 or 2, most commonly local erythema, flushing, pruritis and hypotension, 
most resolving within minutes of injection.  Related grade 3 (3 patients) or 4 (1) allergic/anaphylaxis 
adverse event occurred and resolved without sequelae. Best response in 44 injected lesions in 20 
evaluable patients included 2 complete responses, > 50% reduction in 5 tumours, and 20 stable 
(injected). Significant increases in TILs occurred in 67% (14 of 21) patients with biopsies of injected 
tumours available. Regression of distant non-injected tumour has been observed clinically on biopsy 
(abscopal effect). No RECIST response in non-injected tumours has been observed in 16 evaluable 
patients. Stable disease (median duration 14 weeks) occurred in 50% of patients as best response 
(melanoma (4), sarcoma (3), breast (1)).   
Conclusions: This phase 1 study demonstrates that intratumoural LTX-315 has a manageable safety 
profile and induces increases in TILs in heavily pre-treated patients. Partial and complete regression 
was seen in some injected tumours. Evaluation of LTX-315 in combination with ICIs in breast and 
melanoma is ongoing. 
 
